BeiGene Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (12)

Latest Posts

About This Stock More About This Stock
3 Soaring Hot Stocks With Big Insider Buying
Article By: TipRanks
Thursday, August 24, 2017 1:30 PM EST
Let’s check out the three soaring stocks that are seeing particularly interesting insider buying right now.
In this article: MYOK, BGNE, IPI Also: CELG
Read
Week In Review: Beigene Sets Record With $1.4 Billion Celgene Deal
Article By: ChinaBio® Today
Saturday, July 8, 2017 2:35 PM EST
BeiGene of Beijing has entered a "transformational" collaboration with Celgene which involves BeiGene's clinical-stage PD-1 immuno-oncology drug, has a total value of almost $1.4 billion.
In this article: CELG, QGEN, BGNE, BYSI, ATNX
Read
Beijing-Based BeiGene Study Of PD-1 Antibody For Patients With Relapsed Or Refractory Hodgkin Lymphoma Underway
Article By: Lorimer Wilson
Sunday, April 23, 2017 1:47 AM EST
Beijing-based BeiGene has dosed their first patient with refractory classical Hodgkin lymphoma — or cHL — in their Phase I PD-1 checkpoint trial of the drug BGB-A317 in a pivotal study which started less then four months ago.
In this article: BGNE Also: AZN, BMY, MRK, PFE, RHHBY, INCY, AGEN, TGTX
Read
Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
Article By: ChinaBio® Today
Saturday, April 22, 2017 3:40 PM EST
Tianjin CanSino Biologics, a vaccine developer, raised $65 Million in its latest funding round. Currently, CanSino is testing four products in Phase I to III clinical trials, conducted in North America, Africa and China respectively.
In this article: MRK, PFE, CELG, IONS, BGNE
Read
Week In Review: Fosun Eyeing $4 Billion Bid For Germany's Stada Pharma
Article By: ChinaBio® Today
Saturday, March 11, 2017 1:52 PM EST
Shanghai Fosun Pharma is said to be contemplating a bid for Germany's Stada Arzneimittel, a well established generic drug company.
In this article: BGNE, BYSI
Read

PARTNER HEADLINES

Latest Tweets for $BGNE

No tweets yet!